同步鼻塞式呼吸机联合肺表面活性物质治疗临床对照研究  

Comparative study of synchronized nasal respirator combined with pulmonary surfactant in the treatment of premature infants with HMD

作　　者：王依[1] 陈群娣[1] 

机构地区：[1]广东省博罗县人民医院儿科,广东博罗516100

出　　处：《中国医药科学》2013年第9期187-188,208,共3页China Medicine And Pharmacy

摘　　要：目的探讨在肺透明膜病早产儿中予同步鼻塞式呼吸机(NCPAP)联合肺表面活性物质(PS)的临床疗效。方法选取2011年8月～2013年6月入住该院NICU确诊的HMD早产儿共62例,按随机数字表分为观察组及对照组各31例,观察组予PS+NCPAP治疗,对照组予沐舒坦(MU)+NCPAP治疗,对比两组患者间临床资料差异性。结果观察组住院时间、呼吸机使用时间、呼吸困难缓解时间均较对照组短,治疗36h后观察组血气分析明显优于对照组。近期并发症观察组较对照组肺炎、颅内出血、肺出血、支气管肺发育不良发生率分别低:25.81%、16.12%、16.12%、16.12%,远期并发症观察组较对照组脑性瘫痪发生率低16.12%。结论 NCPAP联合PS治疗是早产儿HMD良好的临床方案,临床效果佳、安全性较高。Objective To investigate the clinical efficacy of synchronized nasal respirator combined with pulmonary surfactant in the treatment of premature infants with hyaline membrane disease. Methods From August 2011 to June 2013, a total of 62 premature infants with HMD confirmed by NICU in our hospital were randomly divided into observation group given PS＋NCPAP treatment, and control group given MU＋NCPAP treatment, with 31 cases in each. The clinical differences between the two groups were compared. Results The hospitalization time, mechanical ventilation time, dyspnea remission time in observation group were shorter than those in control group; the blood gas analysis in observation group after 36 hours＇ treatment was better than that in control group. The incidence of short- term complications （including pneumonia, intracranial hemorrhage, pulmonary hemorrhage, bronchopulmonary dysplasia ） in observation group was lower than that in control group （25.81%,16.12%, 16.12%, 16.12% respectively ）, the incidence of cerebral palsy of long-term complications in observation group was lower than that in control group （16.12%）. Conclusion NCPAP combined with PS has good clinical efficacy and high security, and is a good clinical project of treatment in preterm infants with HMD.

关 键 词：同步鼻塞式 肺表面活性物质 肺透明膜病 早产儿 沐舒坦 

分 类 号：R722.1[医药卫生—儿科]